Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jul-Sep;5(3):211-4.

The use of transvaginal sonography and vaginoscopic hysteroscopy in women on tamoxifen

M Paschopoulos  1 , E Kontostolis, E D Lolis, G Koliopoulos, Y Alamanos, E Paraskevaidis
Affiliations

The use of transvaginal sonography and vaginoscopic hysteroscopy in women on tamoxifen

M Paschopoulos et al. JSLS. 2001 Jul-Sep.

Abstract

Background and objectives: Long-term administration of tamoxifen causes endometrial changes. The aim of this study was to evaluate the role of transvaginal sonography and vaginoscopic hysteroscopy in the screening of patients on tamoxifen.

Methods: Seventy patients with breast cancer treated with tamoxifen 20 mg daily underwent transvaginal sonography and vaginoscopic hysteroscopy, a modified relatively painless approach, at the beginning of the treatment and at a follow-up visit approximately 9 months after its initiation.

Results: At the follow-up visit, the mean uterine dimensions and mean endometrial thickness as measured by ultrasound were significantly larger, and pulsatility and resistance indices of the uterine arteries as measured by Doppler were significantly lower. Sonography revealed abnormal endometrial thickness in 73% (51 of 70) of the patients, and 83% (58 of 70) had hysteroscopical changes. Sonography missed 1 case of endometrial adenocarcinoma.

Conclusions: Vaginoscopic hysteroscopy, an approach that causes reduced pain, can add significantly to the sensitivity of transvaginal sonography for the detection of endometrial changes in patients with breast cancer receiving tamoxifen. It is recommended for every patient prior to the initiation of treatment and at the follow-up visits.

PubMed Disclaimer

References

    1. Kedar R, Bourne T, Powles T, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet. 1994;343:1318–1321 - PubMed
    1. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343:448–452 - PubMed
    1. Selvaggi L, Bettocchi S, Porreca M, Loverro G. A vaginoscopic approach to hysteroscopy. J Am Assoc Gynecol Laparosc. 1995;2:S76 - PubMed
    1. Paschopoulos M, Paraskevaidis E, Stefanidis K, Kofinas G, Lolis D. Vaginoscopic approach to outpatient hysteroscopy. J Am Assoc Gynecol Laparosc. 1997;4:13–15 - PubMed
    1. Franchi M, Ghezzi F, Donadello N, Zanaboni F, Beretta P, Bolis P. Endometrial thickness in tamoxifen treated patients: an independent predictor of endometrial disease. Obstet Gynecol. 1999;93:1004–1008 - PubMed

LinkOut - more resources